Skip to main content
. 2019 Aug 21;2019:2724948. doi: 10.1155/2019/2724948

Table 2.

Univariate and multivariate analyses of disease-free survival and cancer-specific survival for upper tract urothelial carcinomas.

Variables Item Disease-free survival Cancer-specific survival
Univariate Multivariate Univariate Multivariate
HR 95% CI P value HR 95% CI P value HR 95% CI P value HR 95% CI P value
Stage III/IV 1.76 1.01-3.08 0.046 1.18 0.57-2.44 0.661 6.03 2.17-16.80 0.001 4.18 1.00-17.51 0.051
I/II 1.00 1.00 1.00 1.00

Grade High 1.15 0.61-2.17 0.659 1.05 0.50-2.22 0.902 1.65 0.55-4.99 0.376 0.63 0.14-2.86 0.547
Low 1.00 1.00 1.00 1.00

Gender Male 1.24 0.71-2.16 0.456 1.18 0.64-2.16 0.596 1.36 0.55-3.36 0.501 0.89 0.32-2.43 0.815
Female 1.00 1.00 1.00 1.00

Age (years) ≥65 1.68 0.92-3.05 0.091 1.54 0.78-3.07 0.216 1.43 0.54-3.77 0.470 1.11 0.33-3.72 0.870
<65 1.00 1.00 1.00 1.00

Tumor location Renal pelvis + ureter 1.39 0.68-2.83 0.364 1.47 0.64-3.37 0.365 1.11 0.37-3.32 0.856 1.33 0.31-5.82 0.701
Renal pelvis 0.76 0.40-1.45 0.406 0.67 0.34-1.31 0.243 0.56 0.19-1.68 0.301 0.42 0.13-1.34 0.143
Ureter 1.00 1.00 1.00 1.00

Tumor side Left 0.80 0.46-1.40 0.443 0.84 0.46-1.55 0.584 0.59 0.24-1.48 0.263 0.43 0.14-1.29 0.131
Right 1.00 1.00 1.00 1.00

Lymphovascular invasion Positive 1.35 0.72-2.55 0.351 1.13 0.54-2.39 0.745 2.49 0.97-6.34 0.057 2.15 0.69-6.70 0.186
Negative 1.00 1.00 1.00 1.00

Creatinine (mg/dl) >1.5 1.06 0.60-1.88 0.844 0.93 0.50-1.73 0.822 0.76 0.29-2.00 0.570 0.59 0.19-1.76 0.342
≤1.5 1.00 1.00 1.00 1.00

CSF-1 High 2.14 1.20-3.81 0.010 2.56 1.30-5.04 0.007 5.18 1.71-15.71 0.004 5.14 1.27-20.84 0.022
Low 1.00 1.00 1.00 1.00

Abbreviations: HR: hazard ratio; CI: confidence interval.